EMA Authorised: Austedo (deutetrabenazine) — Teva GmbH

View source ↗

Summary

The European Medicines Agency authorised Austedo (deutetrabenazine) for the treatment of tardive dyskinesia, with Teva GmbH as the marketing authorization holde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• AUSTEDO (deutetrabenazine)

Snippet

Status: Authorised. Therapeutic area: Tardive Dyskinesia. MAH: Teva GmbH. Decision date: 08/01/2026